1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Omeros Corporation

Omeros Corporation

OMER
Omeros CorporationUS flagNASDAQ Global Market
9.53
USD
-0.10
- -
689.74MMarket Cap
Omeros Corporation
OMER
(NASDAQ Global Market)

Recent

price

9.53

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.1
0.2
0.25
0.06
0.02
0.36
1.03
1.42
0.61
- -
- -
- -
- -
- -
- -
- -
0.15
Revenue per Share
-1.37
-1.29
-1.59
-1.39
-2.22
-2
-1.65
-1.17
-2.61
-1.71
-2.41
3.12
0.76
-1.88
-2.7
-0.05
1.29
Basic EPS, GAAP
-1.07
-1.21
-1.46
-1.05
-1.75
-1.74
-1.28
-0.8
-2.15
-1.22
-1.76
-1.76
-1.38
1.18
-2.56
-1.83
-1.42
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-6.88
-7.92
-8.87
-8.9
-9.86
-10.72
-11.61
-11.48
-13.37
-14.82
-15.25
-10.95
-10.12
-12
-15.64
-14.38
-12.81
Book Value per Share
0.96
-0.25
-0.27
-0.64
-1.28
-0.7
-0.93
-0.06
-2.06
-2.2
-2.11
0.38
1.37
-0.4
-3.14
-1.91
-0.95
Tangible Book Value per Share
21
22
24
29
33
38
40
46
49
50
57
62
63
63
58
64
67
Basic Weighted Avg Shares
2
5
6
2
1
14
42
65
30
- -
- -
- -
- -
- -
- -
- -
10
Sales/Revenue/Turnover
-1,430.21
-605.88
-612.5
-3,157.25
-12,988.5
-527.34
-130.42
-67.71
-375.73
- -
- -
- -
- -
- -
- -
- -
-1,063.86
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
1
1
2
2
1
1
1
1
1
1
Depreciation Expense
-29
-29
-38
-40
-74
-75
-67
-53
-127
-84
-138
194
47
-118
-157
-3
86
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.07
Effective Tax Rate (%)
-1,389.6
-630.99
-638.39
-2,487.25
-13,668.46
-555.9
-160.38
-82.5
-424.39
- -
- -
- -
- -
- -
- -
- -
871.02
Profit Margin (%)
28
7
16
3
-9
21
44
82
53
48
115
196
307
165
55
138
121
Working Capital
9
14
20
15
26
50
80
84
151
191
265
343
243
231
180
216
142
LT Debt
20
-6
-7
-18
-43
-26
-37
-3
-100
-109
-121
24
86
-25
-183
-121
-63
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-273.23
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-12.72
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
23
23
6
LT Borrowings
160
209
137
LT Finance Leases
9
7
6
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
70
72
72
Market Capitalization
247
1,090
706

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
72
216
180
Cash, Cash Equivalents & STI
36
172
135
Accounts Receivable, Net
6
6
12
Inventories
- -
- -
- -
Total Current Liabilities
81
78
59
Payables & Accruals
26
21
21
ST Debt
23
23
6
Deferred Revenue
- -
2
3

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
403.78%
121.76%
-33.61%
Free Cash Flow
-36.11%
-104%
-22.02%
Net Income, GAAP
-59.34%
-145.9%
-97.86%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
10
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.63
-0.97
-0.56
-0.54
-2.7
2025
-0.58
-0.43
-0.47
1.22
-0.05
2026
0.78
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Midatech Pharma plc (MTPH.L)
Windtree Therapeutics, Inc. (WINTW)
Y-mAbs Therapeutics, Inc. (YMAB)
bluebird bio, Inc. (BLUE)
ZIOPHARM Oncology, Inc. (ZIOP)
Absci Corporation (ABSI)
Business
Omeros Corporation Omeros Corporation (Nasdaq: OMER), founded in 1994 and headquartered in Seattle, Washington, operates as a clinical-stage biopharmaceutical company that discovers, develops, and commercializes small-molecule and protein therapeutics targeting immunologic disorders including complement-mediated diseases, cancers, addictive and compulsive disorders, and central nervous system conditions; its approved product OMIDRIA (phenylephrine and ketorolac intraocular solution 1%/0.3%) maintains pupil size and reduces postoperative pain in patients undergoing cataract surgery or intraocular lens replacement; lead pipeline candidates include the MASP-2 inhibitor narsoplimab (OMS721) under FDA review for hematopoietic stem cell transplant-associated thrombotic microangiopathy, the long-acting MASP-2 inhibitor OMS1029 in Phase 1, small-molecule inhibitors of MASP-2, MASP-3 and MASP-2/3, the PDE7 inhibitor OMS527 in clinical development for cocaine use disorder funded by the National Institute on Drug Abuse, PPAR gamma (PPARγ) agonists such as OMS405 for addiction disorders including opioids, nicotine and alcohol, GPR174 inhibitors and cellular therapies enhancing T-cell function for immuno-oncology applications, and other programs leveraging its proprietary GPCR platform for orphan and large-market indications with operations primarily in the United States. In recent developments, Omeros entered a definitive agreement in October 2025 with Novo Nordisk for the asset purchase and license of its clinical-stage MASP-3 inhibitor zaltenibart (OMS906) targeting paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy, providing up to $2.1 billion in upfront, milestone and royalty payments while retaining rights to certain preclinical MASP-3 programs; the company also announced agreements in May 2025 to acquire $80.5 million of its convertible senior notes due 2026 and convert an additional $10 million into common stock to strengthen its balance sheet ahead of potential narsoplimab commercialization.

Company News

APIChatGPT

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

  • globenewswire.com

    Omeros Corporation Investigated by the Portnoy Law Firm

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

  • fool.com

    Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026?

  • globenewswire.com

    OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

  • businesswire.com

    OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

  • invezz.com

    Omeros stock crashes on regulatory setback: buy the dip?

  • benzinga.com

    FDA Approved, Europe Unconvinced: Omeros' Stem Cell Transplant Treatment Hits Regulatory Divide

  • businesswire.com

    Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA

  • fool.com

    NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?

  • fool.com

    Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?

  • businesswire.com

    Omeros Announces Webcast Details for Annual Meeting of Shareholders

  • zacks.com

    Bears are Losing Control Over Omeros (OMER), Here's Why It's a 'Buy' Now

  • marketbeat.com

    Omeros Q1 Earnings Call Highlights

  • seekingalpha.com

    Omeros Corporation (OMER) Q1 2026 Earnings Call Transcript